
|Videos|September 30, 2022
Role of Cabozantinib and Nivolumab in Advanced RCC
Author(s)Daniel J. George, MD
Dr Daniel J George reviews long term follow up data from the CHECKMATE 9ER and the implications of the data in the treatment paradigm for patients with advanced renal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
5



















